Literature DB >> 6264985

A simulated study of historical controls using real data.

V T Farewell, G J D'Angio.   

Abstract

Data from the first and second National Wilms' Tumor study were used to simulate how use of the first study's historical controls in the design and analysis of the second study might have influenced the conclusions of the investigations. It was seen that the conclusions from a fully-randomized study can differ in substances from one using historical controls.

Entities:  

Mesh:

Year:  1981        PMID: 6264985

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  9 in total

1.  Assessing effects on long-term survival after early termination of randomized trials.

Authors:  Y Shen; T R Fleming
Journal:  Lifetime Data Anal       Date:  1999       Impact factor: 1.588

2.  Access and Health System Impact of an Early Intervention Treatment Program for Emerging Adults with Mood and Anxiety Disorders.

Authors:  Kelly K Anderson; Ava John-Baptiste; Arlene G MacDougall; Lihua Li; Paul Kurdyak; Elizabeth A Osuch
Journal:  Can J Psychiatry       Date:  2018-11-12       Impact factor: 4.356

3.  Survival trial design and monitoring using historical controls.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Pharm Stat       Date:  2016-06-15       Impact factor: 1.894

4.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  Richard B Womer; Daniel C West; Mark D Krailo; Paul S Dickman; Bruce R Pawel; Holcombe E Grier; Karen Marcus; Scott Sailer; John H Healey; John P Dormans; Aaron R Weiss
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

Review 5.  The National Wilms Tumor Study: a 40 year perspective.

Authors:  Giulio J D'Angio
Journal:  Lifetime Data Anal       Date:  2007-11-20       Impact factor: 1.588

Review 6.  Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.

Authors:  Lindsay A Renfro; Lingyun Ji; Jin Piao; Arzu Onar-Thomas; John A Kairalla; Todd A Alonzo
Journal:  JCO Precis Oncol       Date:  2019-10-24

7.  Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.

Authors:  Regina I Jakacki; Kenneth J Cohen; Allen Buxton; Mark D Krailo; Peter C Burger; Marc K Rosenblum; Daniel J Brat; Ronald L Hamilton; Sandrah P Eckel; Tianni Zhou; Robert S Lavey; Ian F Pollack
Journal:  Neuro Oncol       Date:  2016-03-22       Impact factor: 12.300

8.  Cancer immunotherapy trials: leading a paradigm shift in drug development.

Authors:  Leisha A Emens; Lisa H Butterfield; F Stephen Hodi; Francesco M Marincola; Howard L Kaufman
Journal:  J Immunother Cancer       Date:  2016-07-19       Impact factor: 13.751

9.  Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report.

Authors:  Neyssa Marina; Linda Granowetter; Holcombe E Grier; Richard B Womer; R Lor Randall; Karen J Marcus; Elizabeth McIlvaine; Mark Krailo
Journal:  Sarcoma       Date:  2015-10-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.